Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS.

J, Kuhle; N, Daizadeh; P, Benkert; A, Maceski; C, Barro; Z, Michalak; MP, Sormani; J, Godin; S, Shankara; TA, Samad; A, Jacobs; L, Chung; N, Rӧsch; C, Kaiser; CP, Mitchell; D, Leppert; E, Havari; L, Kappos

doi:10.1177/13524585211032348

Public

Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS.

Shared by NobleBlocks on Aug 11, 2021 • 12:00 AM UTC

Authors:

Kuhle J

Daizadeh N

Benkert P

Abstract

<h4>Background</h4>Alemtuzumab efficacy and safety was demonstrated in CARE-MS I and extension studies (CAMMS03409; TOPAZ).<h4>Objective</h4>Evaluate serum neurofilament light chain (sNfL) in CARE-MS I patients and highly active disease (HAD) subgroup, over 7 and 2 years for alemtuzumab and subcutan...

Subject

Multiple sclerosis

Biomarkers

Alemtuzumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!